Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have received an average rating of “Hold” from the twenty-three analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $384.6667.
A number of equities research analysts have recently commented on the company. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Truist Financial decreased their price objective on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a report on Monday. Guggenheim decreased their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th.
View Our Latest Analysis on Elevance Health
Institutional Investors Weigh In On Elevance Health
Elevance Health Trading Up 1.5%
NYSE ELV opened at $316.07 on Tuesday. The stock has a market capitalization of $69.43 billion, a price-to-earnings ratio of 12.58, a PEG ratio of 1.71 and a beta of 0.49. Elevance Health has a one year low of $273.71 and a one year high of $443.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The business’s fifty day moving average is $310.73 and its 200-day moving average is $332.12.
Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts predict that Elevance Health will post 33.96 EPS for the current year.
Elevance Health Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were issued a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.2%. Elevance Health’s payout ratio is 27.39%.
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
